Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.

• MeSH
• akvaporin 4 genetika   MeSH
• humanizované monoklonální protilátky terapeutické užití   MeSH
• imunoglobulin G MeSH
• lidé MeSH
• neuromyelitis optica * farmakoterapie   genetika   MeSH
• receptory IgG genetika   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• akvaporin 4 MeSH
• FCGR3A protein, human MeSH Prohlížeč
• humanizované monoklonální protilátky MeSH
• imunoglobulin G MeSH
• inebilizumab MeSH Prohlížeč
• receptory IgG MeSH